Marker Therapeutics, Inc. (MRKR) earnings
MRKR earnings moved a median of -4.01% by the close. Quarterly and annual MRKR reports and results, each read against the price at its own news timestamp. Back to the MRKR overview →
16 measured MRKR earnings events.
Where these MRKR earnings landedvs 16 measured MRKR earnings reactions
| Middle 50% of MRKR earnings reactions | -8.56% to -2.01% |
|---|---|
| Median reaction (to close) | -4.01% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 MRKR earnings events with a measured close landed between -8.56% and -2.01%; 6% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Marker Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.85% | -1.70% | |
| Form 10-Q Marker Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.70% | -2.11% | |
| Form 10-K Marker Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.12% | -1.49% | |
| Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | -3.33% | +2.56% | |
| Form 10-Q Marker Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.31% | -4.54% | |
| Form 10-Q Marker Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.83% | -3.48% | |
| Form 10-K Marker Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.40% | -0.81% | |
| Form 10-Q Marker Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -10.76% | |
| Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | +0.00% | -10.76% | |
| Form 10-Q Marker Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -6.75% | |
| Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates | Press release | +0.00% | -6.75% | |
| Form 10-Q Marker Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.84% | |
| Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates | Press release | +0.00% | -2.84% | |
| Form 10-K Marker Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.02% | -10.00% | |
| Form 10-Q Marker Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | — | -8.56% | |
| Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates | Press release | — | -8.56% |
Keep exploring
More MRKR: analyst actions → · SEC filings → · MRKR overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CARL ZEISS MEDI UNSP/ADR (CZMWY) | 120 | -0.21% | 21% |
| HEMP NATURALS INC (HPMM) | 120 | 0.00% | 37% |
| ChromaDex Corporation (CDXC) | 118 | +0.80% | 61% |
| ADHERA THERAPEUTICS INC (ATRX) | 117 | 0.00% | 23% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.